




EYEPOINT®  
PHARMACEUTICALS



# Forward-Looking Statements

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our partnerships and strategic alliances with other companies, as well as the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a sustained delivery treatment for wet age-related macular degeneration and non-proliferative diabetic retinopathy; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the extent to which COVID-19 impacts our business; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ® and DEXYCU®; the success of current and future license agreements, including our agreements with Ocumension Therapeutics, Equinox Science and Betta Pharmaceuticals; termination or breach of current license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

# Compelling Pipeline Leverages Proven Durasert® Technology

## **EYP-1901 is key pipeline program**

- Vorolanib, a TKI in bioerodible Durasert
- Positive safety and efficacy data from Phase 1 DAVIO clinical trial
- Phase 2 DAVIO 2 clinical trial in wet AMD dosed in July 2022; non-proliferative diabetic retinopathy (NPDR) PAVIA trial expected to begin in Q3 2022

## **Durasert® - proven intravitreal (IVT) drug delivery**

- Sustained ocular drug delivery
- Constant (zero-order kinetics) stable release of drug
- Safely administered to over 80,000 patient eyes across four FDA approved products

## **Strong balance sheet with growing revenue**

- \$171 million in cash and investments on June 30, 2022
- Cash runway into 2H 2024
- Commercial franchise positioned for 2022 break-even

TECHNOLOGY

# DURASERT®



## Safe Sustained Intravitreal Drug Delivery

- Used in four of six FDA approved intravitreal sustained delivery products
- Delivered by a single in-office intravitreal injection
- Continuous, stable release of drug


### Non-Erodible Products

- YUTIQ® (EyePoint)
- ILUVIEN® (Alimera)
- RETISERT® (B&L)
- VITRASERT® (B&L)

### Bioerodible: EYP-1901

- Polyimide coating eliminated
- Initial drug burst from insert surface
- Constant, zero-order kinetic release over months

# EYP-1901: Vorolanib in Bioerodible Durasert<sup>®</sup>



EYP-1901 insert at month 5 post-injection

## EYP-1901

- Single IVT injection of up to 3 inserts
- Bioerodible formulation of Durasert
- Initial drug burst from surface of insert to rapidly reach therapeutic levels in ocular tissues
- Zero order kinetics release


## Vorolanib

- Receptor-binding tyrosine kinase inhibitor (TKI)
- Binds receptors of all VEGF growth factors
- Oral formulation studied in Phase 1 and Phase 2 wet AMD clinical trials<sup>1,2</sup>

1. Jackson et al. JAMA Ophthalmol 2017. 2. Cohen MN et al. Br J Ophthalmol. 2021.

# EYP-1901 utilizes a bioerodible formulation of Durasert for repeated IVT injections

- Sustained, zero-order kinetics drug release over 6-9 months in bioerodible
- High drug load per insert
- Insert is ~1/5,000 the volume of the vitreous



## WHY VOROLANIB?


Vorolanib is a specifically designed TKI for reduced off-target binding

## Vorolanib selected after evaluation of over 100 small molecule TKIs

- Previously studied in Phase 1 and Phase 2 clinical trials as an oral therapy with compelling efficacy data and no ocular toxicity
- Intracellular binding of all VEGF receptors thereby blocking receptors of all VEGF family of growth factors with strong affinity to VEGF receptor 2
- Reduced off-target binding of receptors associated with TKI systemic side effects

# Vorolanib binds receptors of all VEGF growth factors with strong affinity to VEGF receptor 2 - a receptor associated with blood vessel leakage

## VEGF SIGNALING PATHWAYS



## VOROLANIB INHIBITS VEGFR

- Binds to the intracellular domain of tyrosine kinases
- Targets the angiogenic VEGF receptors R1, R2 and R3 with high potency



EYP-1901

# PHASE 1 DAVIO CLINICAL TRIAL 12 MONTH RESULTS


# EYP-1901 Phase 1 DAVIO clinical trial enrolled 17 patients over four different dosages

## Primary Endpoint: Safety

- Ocular and non-ocular TEAEs through month-12

## Secondary Endpoints

- Supplemental anti-VEGF therapy through 6-months
- Change in BCVA from baseline
- CST as measured by OCT



# EYP-1901 Phase 1 DAVIO clinical trial demonstrated favorable overall safety data at 12-months meeting primary endpoint

## Ocular AEs of particular interest:

- No vitreous floaters
- No endophthalmitis
- No retinal detachment
- No implant migration in the anterior chamber
- No retinal vasculitis
- No posterior segment inflammation


## Ocular AEs observed:

- One eye: mild asymptomatic anterior chamber cell/flare;
  - ▶ treated with Maxitrol<sup>®</sup> eyedrops – resolved in 8 days – no sequelae or recurrence
- One eye: asymptomatic vitreous hemorrhage from injection; observed

- No ocular serious adverse events (SAEs)
- No drug-related systemic SAEs
- No evidence of vorolanib-related ocular or systemic toxicity
- No Durasert-related toxicity or tolerance issues
- No dose limiting toxicity

# EYP-1901 phase 1 DAVIO clinical trial demonstrated clinically significant reduction in treatment burden of 79% at 6-months

SOC ANTI-VEGF INJECTIONS BEFORE AND AFTER TREATMENT




REDUCTION IN AVERAGE MONTHLY TX BURDEN

DOSE	%
LOW DOSE (N=3)	-70%
LOW MID DOSE (N=3)	-100%
MID DOSE (N=3)	-89%
HIGH DOSE (N=5)	-55%

- Anti-VEGF ● SoC (Anti-VEGF)+ EYP1901
- No rescue injection given □ Missed visit

# EYP-1901 Phase 1 DAVIO clinical trial continues clinically significant reduction in treatment burden of 74% at 12-months

## SOC ANTI-VEGF INJECTIONS BEFORE AND AFTER TREATMENT



Interim data – monitored through 4 months


MONTHS

## REDUCTION IN AVERAGE MONTHLY TX BURDEN

DOSE	12 MOS
LOW DOSE (N=3)	-66%
LOW MID DOSE (N=1)	-100%
MID DOSE (N=8)	-88%
HIGH DOSE (N=5)	-47%

- Anti-VEGF ● SoC (Anti-VEGF)+ EYP1901
- No rescue injection given □ Missed visit

# EYP-1901 Phase 1 DAVIO clinical trial demonstrated that 53% of patients did not require supplemental anti-VEGF treatment at 6-months




# EYP-1901 Phase 1 DAVIO clinical trial met all objectives

## FAVORABLE SAFETY PROFILE

- No ocular SAEs reported
- No drug-related systemic SAEs reported
- Ocular AEs – majority are mild and expected

## POSITIVE EFFICACY & DURABILITY

- Stabilization of mean BCVA and OCT throughout 6 months was achieved
- 53% supplemental anti-VEGF injection free up to 6-months
- 79% reduction in treatment burden at 6-months



**SIX MONTHS MEDIAN TIME  
TO SUPPLEMENTAL ANTI-  
VEGF**

EYP-1901


# TREAT TO MAINTAIN

---



# EYP-1901 demonstrated clinically significant reduction in treatment burden of 79% at 6 Months supporting treat to maintain positioning

## SOC ANTI-VEGF INJECTIONS BEFORE AND AFTER TREATMENT



## TREAT TO MAINTAIN WITH EYP-1901

- About half of eyes in DAVIO could go up to 6 months on EYP-1901 alone
- Another ~30% received only a single supplemental anti-VEGF during 6-months
- About 15 % failed both SoC and 1901 and required multiple supplements

# EYP-1901 positioned as a potential “Treat-to-Maintain” therapy

- *Treat* initially with current anti-VEGF standard of care until VA is maximally improved and retina is as dry as possible (induction phase)
- *Maintain* with EYP-1901 every six months, supplementing if needed with current anti-VEGF biologic
- Based on DAVIO, we believe over half of all wet AMD eyes may be maintained visually and anatomically with EYP-1901 alone
- Another large segment may require occasional supplemental anti-VEGF but a much-reduced interval

# WET AMD PHASE 2 TRIAL (DAVIO 2)

---

# EYP-1901 DAVIO 2 clinical trial is non-pivotal randomized, double-masked, aflibercept controlled



● REQUIRED AFLIBERCEPT INJECTION VISIT


● VISIT SCHEDULED

● EYP-1901 DOSING

# NPDR PHASE 2 CLINICAL TRIAL (PAVIA)

---

# EYP-1901 Phase 2 NPDR clinical trial is non-pivotal, randomized double-masked, day-one single injection with sham control



# FDA Approved YUTIQ

---

## PRODUCTS



**CONTINUOUS CALM  
IN UVEITIS**

# Approved for the Treatment of Chronic Non-Infectious Uveitis Affecting the Back of the Eye



- Commercially launched in U.S. in 2019
- Patent protection to August 2027
- Constant and stable release of fluocinolone with Durasert helps prevent uveitis flares for up to 3 years

### LICENSE AGREEMENTS

Alimera Sciences, Inc. has rights for non-infectious posterior uveitis in the EMEA

Rights for China, Hong Kong, Taiwan, Macau, Korea and certain SE Asia countries licensed to Ocumension Therapeutics with a royalty on sales payable to EyePoint



## PRODUCTS



# Chronic Non-Infectious Uveitis Causes Blindness With Every Flare

60K–100K patients are suffering from posterior segment uveitis in the U.S.

## The need

- Flares can cause blindness
- 30,000 Americans become blind each year because of uveitis
- Uveitis lasts a lifetime and often affects people in middle age
- Conventional treatment is burdensome for patients and caregivers

## The YUTIQ answer

- 3-year continuous treatment in a single injection that controls flares and preserves eyesight
- Simple administration in the physician's office
- Gives patients and physicians the confidence that comes with three years of assured compliance


# Continuous 3-year Delivery Limits Blindness-Causing Uveitis Flares

## PRODUCTS



**CONTINUOUS CALM  
IN UVEITIS**

## Time to recurrence of uveitis within 36 months



# Solid cash position and growing revenues

## Balance Sheet – June 30, 2022

- \$171 million of cash and investments
- \$40 million of short and long-term debt

## Financial Performance\*

- \$11.3 million of net product revenues in Q2 2022, a 30% increase over Q2 2021
- Q2 2022 Customer demand
  - ~900 units of YUTIQ a 43% increase over Q1 2022
  - ~14,700 units of DEXYCU consistent with Q1 2022
- Commercial franchise projected to break-even in 2022
- Cash runway into 2H 2024



EYEPOINT®  
PHARMACEUTICALS

